Article
Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells.
Proceedings of the National Academy of Sciences of the United States of America - 1 Aug 1990
Sykes M, Romick M L, Sachs D H
Abstract excerpt
We have recently demonstrated that interleukin 2 (IL-2), when administered in high doses for several days beginning on the day of allogeneic bone marrow transplantation (BMT), markedly diminishes graft-versus-host disease (GVHD) mortality in lethally irradiated mice. An optimal anti-GVHD effect was attained by coadministering T-cell-depleted (TCD) syngeneic marrow. We demonstrate here that the full...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.